We are Seeking Collaboration Partnerships

As a clinical development stage company, we are conducting human clinical testing of our lead product INT230-6 in refractory solid tumor cancers. We have interest in collaborating with pharmaceutical, imaging or biotechnology companies. In particular we would like to test combinations of our novel drug with products that may be synergistic. Data reported by Intensity Therapeutics have shown INT230-6 is synergistic with checkpoint blockage antibodies including anti-CTLA-4 and anti-PD-1 compounds.

Back to Top